Moleculin Biotech (MBRX) Net Equity Issued and Repurchased (2016 - 2023)

Moleculin Biotech's Net Equity Issued and Repurchased history runs 5 years deep, the most recent figure standing at -$11000.0 for Q4 2023.

• In Q4 2023, Net Equity Issued and Repurchased changed N/A year-over-year to -$11000.0; the TTM figure through Jun 2024 stood at -$11000.0 (down 105.21% YoY), while the FY2023 annual figure was $200000.0, changed N/A from the prior year.
• Net Equity Issued and Repurchased for Q4 2023 stood at -$11000.0, down from $70000.0 in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $74.7 million in Q1 2021, with the low at -$11000.0 in Q4 2023.
• The 4-year median for Net Equity Issued and Repurchased is $3.5 million (2020), against an average of $9.7 million.
• The sharpest annual moves came in 2020 and 2021: Net Equity Issued and Repurchased soared 3321.15% in 2020, then tumbled 100.02% in 2021.
• Moleculin Biotech's Net Equity Issued and Repurchased stood at $52000.0 in 2019, then soared by 10446.15% to $5.5 million in 2020, then sank by 100.02% to -$1000.0 in 2021, then plunged by 1000.0% to -$11000.0 in 2023.
• Business Quant data shows MBRX's Net Equity Issued and Repurchased at -$11000.0 in Q4 2023, $70000.0 in Q2 2023, and $141000.0 in Q1 2023.